[18F]FDG-PET/CT atypical response patterns to immunotherapy in non-small cell lung cancer patients: long term prognosis assessment and clinical management proposal
European Journal of Nuclear Medicine and Molecular Imaging · 2024-10 · 51 (12) · 3696-3708
DOI: 10.1007/s00259-024-06794-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 19.06.2024. Verfasst von Mathilde Masse und 8 weiteren Autor:innen. Beteiligte Einrichtung: Centre Antoine Lacassagne, Nuclear Medicine Department, 33 Avenue de Valombrose, 06100, Nice, France. mathilde-m@outlook.fr. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18, Lung Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Aim
To determine the long-term prognosis of immune-related response profiles (pseudoprogression and dissociated response), not covered by conventional PERCIST criteria, in patients with non-small-cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICPIs).
Methods
109 patients were prospectively included and underwent [ 18 F]FDG-PET/CT at baseline, after 7 weeks (PET interim 1), and 3 months (PET interim 2) of treatment. On PET interim 1, tumor response was assessed using standard PERCIST criteria. In the event of PERCIST progression at this time-point, the study design provided for continued immunotherapy for 6 more weeks. Additional response patterns were then considered on PET interim 2: pseudo-progression (PsPD, subsequent metabolic response); dissociated response (DR, coexistence of responding and non-responding lesions), and confirmed progressive metabolic disease (cPMD, subsequent homogeneous progression of lesions). Patients were followed up for at least 12 months.
Results
Median follow-up was 21 months. At PET interim 1, PERCIST progression was observed in 60% (66/109) of patients and ICPI was continued in 59/66. At the subsequent PET interim 2, 14% of patients showed PsPD, 11% DR, 35% cPMD, and 28% had a sustained metabolic response. Median overall survival (OS) and progression-free-survival (PFS) did not differ between PsPD and DR (27 vs 29 months, p = 1.0; 17 vs 12 months, p = 0.2, respectively). The OS and PFS of PsPD/DR patients were significantly better than those with cPMD (29 vs 9 months, p < 0.02; 16 vs 2 months, p < 0.001), but worse than those with sustained metabolic response (p < 0.001). This 3-group prognostic stratification enabled better identification of true progressors, outperforming the prognostic value of standard PERCIST criteria (p = 0.03). Conclusion [ 18 F]FDG-PET/CT enables early assessment of response to immunotherapy. The new wsPERCIST (“wait and see”) PET criteria proposed, comprising immune-related atypical response patterns, can refine conventional prognostic stratification based on PERCIST criteria.
Trial registration
HDH F20230309081206. Registered 20 April 2023. Retrospectively registered.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre Antoine Lacassagne, Nuclear Medicine Department, 33 Avenue de Valombrose, 06100, Nice, France. mathilde-m@outlook.fr.
- Université Côte D'Azur, CNRS, Inserm, iBV, Nice, France. mathilde-m@outlook.fr.
- Centre Antoine Lacassagne, Nuclear Medicine Department, 33 Avenue de Valombrose, 06100, Nice, France.
- Université Côte D'Azur, CNRS, Inserm, iBV, Nice, France.
- Centre Antoine Lacassagne, Oncology Department, 33 Avenue de Valombrose, 06100, Nice, France.
- TIRO-UMR E 4320, UCA/CEA, 28 Avenue de Valombrose, 06100, Nice, France.
ORCID-Profile: Mathilde Masse
Zitieren
APA
Masse, M., Chardin, D., Tricarico, P., Ferrari, V., Martin, N., Otto, J., Darcourt, J., Comte, V., & Humbert, O. (2024). [18F]FDG-PET/CT atypical response patterns to immunotherapy in non-small cell lung cancer patients: long term prognosis assessment and clinical management proposal. European Journal of Nuclear Medicine and Molecular Imaging, 51(12), 3696-3708. https://doi.org/10.1007/s00259-024-06794-8
Vancouver
Masse M, Chardin D, Tricarico P, Ferrari V, Martin N, Otto J, et al. [18F]FDG-PET/CT atypical response patterns to immunotherapy in non-small cell lung cancer patients: long term prognosis assessment and clinical management proposal. European Journal of Nuclear Medicine and Molecular Imaging. 2024;51(12):3696-3708. doi:10.1007/s00259-024-06794-8
BibTeX
@article{Masse2024,
author = {Masse, Mathilde and Chardin, David and Tricarico, Pierre and Ferrari, Victoria and Martin, Nicolas and Otto, Josiane and Darcourt, Jacques and Comte, Victor and Humbert, Olivier},
title = {[18F]FDG-PET/CT atypical response patterns to immunotherapy in non-small cell lung cancer patients: long term prognosis assessment and clinical management proposal},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2024},
volume = {51},
number = {12},
pages = {3696--3708},
doi = {10.1007/s00259-024-06794-8}
}
EUVIMED